Choice of injection location could be key to stopping HIV
NCT ID NCT07335289
Summary
This study aims to find the best way to deliver a highly effective, twice-yearly HIV prevention injection called lenacapavir. It will test if offering people a choice of where to get their follow-up injections—at home, in the community, or at a clinic—helps them stay on the medication longer compared to only using a clinic. The study will enroll 400 HIV-negative people in Massachusetts who are eligible for HIV prevention medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS USE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital Sexual Health Clinic
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.